Comparison · NCT00798967-sae
Teduglutide vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Teduglutide vs Placebo: serious adverse events. Trial comparisons, record NCT00798967-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00798967-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.357 | 0.23 | 0.508 | wilson | |
| Risk in group 2 | 0.279 | 0.167 | 0.427 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0781 | -0.117 | 0.266 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.28 | 0.682 | 2.4 | log | |
| Odds ratio, group 1 over group 2 | 1.44 | 0.573 | 3.59 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Teduglutide than on Placebo | 12.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Teduglutide | 0.05 mg/kg/day subcutaneous (sc) dose of teduglutide | 15 | 42 | EG000 |
| Group 2 | Placebo | Matching sc dose of placebo to teduglutide | 12 | 43 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Adverse event data were collected for each subject from the time informed consent was signed to end of study. For this reporting of adverse event, the most commonly reported treatment emergent adverse events (>=3 subjects at SOC level) are listed.
Source ClinicalTrials.gov
Trial
- Title
- Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects
- NCT number
- NCT00798967
- Phases
- PHASE3
- Conditions
- Short Bowel Syndrome
- Interventions
- teduglutide, placebo
- Lead sponsor
- Shire
- Results first posted
- 2012-02-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00798967?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00798967-sae